A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients with Sickle Cell Disease: RISE UP Phase 2 Results

被引：2

作者：

Idowu, Modupe ^{[1
]}

Otieno, Lucas ^{[2
]}

Dumitriu, Bogdan ^{[3
]}

Lobo, Clarisse L. C. ^{[4
]}

Thein, Swee Lay ^{[5
]}

Andemariam, Biree ^{[6
]}

Nnodu, Obiageli E. ^{[7
]}

Inati, Adlette ^{[8
]}

Glaros, Alexander K. ^{[9
]}

Olalla Saad, Sara Teresinha ^{[10
,11
]}

Bartolucci, Pablo ^{[12
]}

Colombatti, Raffaella ^{[13
]}

Taher, Ali T. ^{[14
]}

Abboud, Miguel R. ^{[15
]}

Oluyadi, Abdulafeez ^{[16
]}

Iyer, Varsha ^{[16
]}

Yin, Ophelia ^{[17
,18
]}

Morris, Susan ^{[16
]}

Yates, Amber M. ^{[16
]}

Shao, Hui ^{[16
]}

Patil, Spurthi ^{[16
]}

Urbstonaitis, Rolandas ^{[16
]}

Zaidi, Ahmar U. ^{[16
]}

Smith, Wally R. ^{[19
]}

机构：

[1] UTHealth, McGovern Med Sch, Houston, TX USA

[2] Victoria Biomed Res Inst, Kisumu, Kenya

[3] Mid Atlantic Permanente Med Grp, Largo, MD USA

[4] HEMORIO, Div Res, Rio De Janeiro, Brazil

[5] NHLBI, Sickle Cell Branch, Bethesda, MD USA

[6] Univ Connecticut Hlth, New England Sickle Cell Inst, Farmington, CT USA

[7] Univ Abuja, Dept Haematol & Blood Transfus, Coll Hlth Sci, Ctr Excellence Sickle Cell Dis Res & Training, Abuja, Nigeria

[8] Lebanese Amer Univ, Gilbert & Rose Marie Chagoury Sch Med, Byblos & NINI Hosp, Tripoli, Lebanon

[9] Childrens Hosp Michigan, Div Hematol Oncol, Detroit, MI USA

[10] Univ Estadual Campinas, Hematol & Transfus Med Ctr, Hemoctr, Campinas, SP, Brazil

[11] Univ Campinas Unicamp, Campinas, Brazil

[12] Mondor Univ Hosp, Reference Ctr Sickle Cell Dis, Creteil, France

[13] Univ Padua, Pediat Hematol Oncol Unit, Padua, Italy

[14] Amer Univ Beirut, Med Ctr, Beirut, Lebanon

[15] Amer Univ, Dept Pediat & Adolescent Med, Beirut Med Ctr, Beirut, Lebanon

[16] Agios Pharmaceut Inc, Cambridge, MA USA

[17] ITeos Therapeut, Watertown, MA USA

[18] Agios Pharmaceut Inc, Time Res, Cambridge, MA USA

[19] Virginia Commonwealth Univ, Richmond, VA USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-187033

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[31] Isoquercetin for thromboinflammation in sickle cell disease: a randomized double-blind placebo-controlled trial
Lizarralde-Iragorri, Maria A.
Gopalan, Bindu Parachalil
Merriweather, Brenda
Brooks, Jennifer
Hill, Mai
Lovins, Dianna
Pierre-Charles, Ruth
Cullinane, Ann
Dulau-Florea, Alina
Lee, Duck-Yeon
Villasmil, Rafael
Jeffries, Neal
Shet, Arun S.
BLOOD ADVANCES, 2024, 8 (01) : 172 - 182
[32] Transdermal buprenorphine in the treatment of chronic pain: Results of a Phase III, multicenter, randomized, double-blind, placebo-controlled study
Sorge, J
Sittl, R
CLINICAL THERAPEUTICS, 2004, 26 (11) : 1808 - 1820
[33] A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Talactoferrin in Patients With Severe Sepsis
Guntupalli, Kalpalatha
Dean, Nathan
Morris, Peter E.
Bandi, Venkata
Margolis, Benjamin
Rivers, Emanuel
Levy, Mitchell
Lodato, Robert F.
Ismail, Preeti M.
Reese, Amber
Schaumberg, John P.
Malik, Rajesh
Dellinger, R. Phillip
CRITICAL CARE MEDICINE, 2013, 41 (03) : 706 - 716
[34] Secukinumab in Giant Cell Arteritis: A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase 2 Trial
Venhoff, Nils
Schmidt, Wolfgang
Bergner, Raoul
Rech, Juergen
Unger, Leonore
Tony, Hans-Peter
Mendelson, Meryl
Sieder, Christian
Maricos, Meron
Thiel, Jens
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 4130 - 4133
[35] Daridorexant in Japanese patients with insomnia disorder: A phase 3, randomized, double-blind, placebo-controlled study
Uchimura, Naohisa
Taniguchi, Mitsutaka
Ariyoshi, Yu
Oka, Yasunori
Togo, Osamu
Uchiyama, Makoto
SLEEP MEDICINE, 2024, 122 : 27 - 34
[36] Ustekinumab in Patients with Active Psoriatic Arthritis: Results of the Phase 3, Multicenter, Double-Blind, Placebo-Controlled Psummit I Study
Kavanaugh, Arthur
McInnes, Iain B.
Gottlieb, Alice B.
Puig, Lluis
Rahman, Proton
Ritchlin, Christopher T.
Li, Shu
Wang, Yuhua
Mendelsohn, Alan
Doyle, Mittie K.
ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S1083 - S1084
[37] USTEKINUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS OF THE PHASE 3, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED PSUMMIT I STUDY
McInnes, I. B.
Kavanaugh, A.
Gottlieb, A. B.
Puig, L.
Rahman, P.
Ritchlin, C.
Li, S.
Wang, Y.
Mendelsohn, A. M.
Doyle, M. K.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 107 - 107
[38] Doxycycline in Creutzfeldt-Jakob disease: A phase 2, randomized, double-blind, placebo-controlled trial
Brandel, Jean-Philippe
Marcon, Gabriella
Coudert, Mathieu
Tettamanti, Mauro
Welaratne, Arlette
Giacone, Georgio
Azimi, Shohreh
Pietrini, Vladimiro
Fabreguettes, Jean-Roch
Imperiale, Daniele
Aucan, Christophe
Lucca, Ugo
Mallet, Alain
Salmona, Mario
Zerr, Inga
Redaelli, Veronica
Forloni, Gianluigi
Haik, Stephane
Tagliavini, Fabrizio
PRION, 2013, 7 : 62 - 62
[39] A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma
Cui, Chuanliang
Mao, Lili
Chi, Zhihong
Si, Lu
Sheng, Xinan
Kong, Yan
Li, Siming
Lian, Bin
Gu, Kangsheng
Tao, Min
Song, Xin
Lin, Tongyu
Ren, Xiubao
Qin, Shukui
Guo, Jun
MOLECULAR THERAPY, 2013, 21 (07) : 1456 - 1463
[40] Efficacy and safety of anamorelin HCl in NSCLC patients: Results from a randomized, double-blind, placebo-controlled, multicenter phase II study
Temel, J.
Bondarde, S.
Jain, M.
Allen, S.
Mann, W.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S269 - S270

← 1 2 3 4 5 →